insights_auto
Why is A1RG34 up 3.29%?
Dive Deeperchevron_right
A1RG34:BVMF
Argenx Se Bdr
R$165.44
arrow_upward
+3.29%(+5.27) 1D
Oct 9, 10:00:14 AM GMT-3 · BRL
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for A1RG34...
Open
R$165.44
High
R$165.44
Low
R$165.44
Mkt. cap
49.43B
Avg. vol.
59.00
Volume
8.00
52-wk high
R$213.15
52-wk low
R$143.22
Shares outstanding
62.89M
No. of employees
2K
Open
R$165.44
High
R$165.44
Low
R$165.44
Mkt. cap
49.43B
Avg. vol.
59.00
Volume
8.00
52-wk high
R$213.15
52-wk low
R$143.22
Shares outstanding
62.89M
No. of employees
2K
News stories
From web sources and news partners
AD HOC NEWS
·
19 minutes ago
Argenx stock at EUR 724.80, market value USD 50.7 billion
Seeking Alpha
·
32 minutes ago
argenx: The Sjögren's Selloff Looks Overdone (NASDAQ:ARGX)
Yahoo Finance
·
2 hours ago
argenx (ENXTBR:ARGX) Gets Mixed Trial News, Is It Still Overvalued?
Investing.com
·
2 hours ago
H.C. Wainwright reiterates argenx stock buy rating on celiac drug data
Profile
Argenx SE is a Belgian-Dutch pharmaceutical company specializing in immunology. Argenx specializes in the development of antibody therapies for the treatment of autoimmune diseases and cancer. Its work primarily focuses on the development of orphan drugs. Wikipedia
About Argenx Se Bdr
Next call in 13 days
Thu, Oct 22, 9:00 AM
Fiscal period
Q3 2026
EPS / Est. (USD)
- / -$9.78
Revenue / Est. (USD)
- / 1.65B
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 1.15B | 1.31B | 1.31B | 1.54B |
Cost of goods sold | 465.08M | 521.40M | 564.00M | 631.00M |
Cost of revenue | 465.08M | 521.40M | 564.00M | 631.00M |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 336.29M | 429.62M | 355.00M | 417.00M |
Operating expense | 336.29M | 429.62M | 355.00M | 417.00M |
Total operating expenses | 801.37M | 951.02M | 919.00M | 1.05B |
Operating income | 349.97M | 359.56M | 394.00M | 493.00M |
Other non operating income | - | -907.00K | - | -1.00M |
EBT including unusual items | 386.05M | 403.29M | 426.00M | 531.00M |
EBT excluding unusual items | 386.05M | 391.71M | 426.00M | 531.00M |
Income tax expense | 41.80M | -129.66M | 60.00M | 59.00M |
Effective tax rate | 10.83% | -32.15% | 14.08% | 11.11% |
Other operating expenses | - | - | - | - |
Net income | 344.26M | 532.95M | 366.00M | 472.00M |
Net profit margin | 29.90% | 40.67% | 27.88% | 30.63% |
Earnings per share | 5.18 | 8.02 | 5.52 | 7.32 |
Interest and investment income | 42.70M | 44.95M | 44.00M | 48.00M |
Interest expense | -993.00K | - | -1.00M | -1.00M |
Net interest expenses | 41.71M | 44.95M | 43.00M | 47.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 350.35M | 361.38M | 395.82M | 501.50M |
Gain or loss from assets sale | - | - | - | - |